#Taiwan #Hsinchu #JelloX Biotech #T-DXd #HER2-cancer

Revolutionary Changes in Breast Cancer Treatment

Introduction

In the ongoing battle against breast cancer, precise diagnosis is crucial, especially when determining HER2 expression levels. A recent collaboration between JelloX Biotech Inc. and the National Taiwan University Hospital (NTUH) has unveiled promising results using innovative 3D pathology technology.

The Study’s Findings

In a press release dated April 16, 2025, JelloX Biotech, a Taiwanese startup specializing in cancer pathology, reported significant revelations from their study involving breast cancer patients. Their advanced 3D pathology approach reclassified over 50% of tumor sample cases compared to conventional diagnostic techniques. The results demonstrated a heightened ability to detect tumors with HER2-low and HER2-ultralow expressions, potentially leading to more patients receiving optimal treatments such as T-DXd.

Importance of HER2 Detection

HER2 (human epidermal growth factor receptor 2) plays a critical role in breast cancer diagnostics and treatment. Accurate identification of HER2 expression can dramatically influence the therapeutic strategy and prognosis for patients. Traditional methods often lag in sensitivity, increasing the risk of misdiagnosis and missed treatment opportunities. JelloX’s technology aims to rectify this issue.

How 3D Pathology Works

JelloX's 3D pathology uses fluorescent staining techniques to provide a detailed visual representation of the spatial distribution of receptors within mammary duct samples from patients. This method surpasses traditional 2D pathology by allowing for a more comprehensive view, thereby reducing the likelihood of treatment misjudgments based on flawed data.

Expert Opinions

Dr. Yen-Yin Lin, CEO of JelloX, expressed the potential of this technology, stating, "For the specific challenges posed by metastatic breast cancer and the need to accurately identify predictive biomarkers, the high sampling capacity of 3D pathology holds substantial promise." This reflects a significant step forward in making precise HER2 diagnostics accessible, empowering healthcare providers to offer tailored treatments.

Broader Implications for Cancer Treatment

The preliminary data from JelloX's collaboration with NTUH is expected to have broader implications beyond breast cancer. Notably, the study indicated that of patients initially classified as HER2-null, an impressive 66.7% were found to reclassify as HER2-expressing when evaluated with 3D technology. This revelation potentially opens doors for additional therapies that were previously unavailable to these patients due to incorrect classifications.

Future Prospects and Broader Applications

JelloX is preparing to present these findings at the upcoming Global Breast Cancer Conference in South Korea, further showcasing the potential that 3D pathology holds across multiple cancer types. The feedback from recent studies on colorectal and esophageal cancers suggests that their technology may indeed revolutionize diagnostics across various domains of oncology.

Conclusion

As breast cancer remains a prevalent concern globally, advancements like JelloX's 3D pathology represent crucial levers in the fight against this disease. By enhancing HER2 detection accuracy, JelloX is poised to change the landscape of breast cancer treatment, ensuring that more patients receive effective therapies tailored to their individual needs. For healthcare industries, this innovative tool not only optimizes diagnostics but also provides economic efficiencies by minimizing unnecessary treatment interventions.

About JelloX Biotech Inc.

Founded in Hsinchu, Taiwan, JelloX Biotech focuses on transforming cancer pathology through cutting-edge 3D digital imaging and artificial intelligence applications. For more information on their innovative solutions and potential partnerships, visit JelloX's website.